The present status of antibiotic research requires the urgent invention of novel agents that act on multidrug‐resistant bacteria. The World Health Organization has classified antibiotic‐resistant bacteria into critical, high and medium priority according to the urgency of need for new antibiotics. Naturally occurring uridine‐derived “nucleoside antibiotics” have shown promising activity against numerous priority resistant organisms by inhibiting the transmembrane protein MraY (translocase I), which is yet to be explored in a clinical context. The catalytic activity of MraY is an essential process for bacterial cell viability and growth including that of priority organisms. Muraymycins are one subclass of naturally occurring MraY inhibitors. Despite having potent antibiotic properties, the structural complexity of muraymycins advocates for simplified analogues as potential lead structures. Herein, we report a systematic structure‐activity relationship (SAR) study of serine template‐linked, simplified muraymycin‐type analogues. This preliminary SAR lead study of serine template analogues successfully revealed that the complex structure of naturally occurring muraymycins could be easily simplified to afford bioactive scaffolds against resistant priority organisms. This study will pave the way for the development of novel antibacterial lead compounds based on a simplified serine template.

中文翻译：

---

简化的新型莫来霉素类似物；使用丝氨酸模板策略来链接关键药剂师。

抗生素研究的现状要求紧急发明可对多种药物具有耐药性的细菌起作用的新型药物。根据对新抗生素的紧迫性，世界卫生组织已将抗药性细菌分为关键，高和中优先级。天然存在的尿苷衍生的“核苷抗生素”通过抑制跨膜蛋白MraY（转座酶I）显示出对许多优先耐药生物的有希望的活性，这在临床上尚待探索。MraY的催化活性是细菌细胞活力和生长的重要过程，包括优先生物的活力。莫来霉素是天然存在的MraY抑制剂的一类。尽管具有强大的抗生素特性，穆雷霉素的结构复杂性提倡将简化的类似物作为潜在的先导结构。在本文中，我们报告了丝氨酸模板连接的简化穆来霉素型类似物的系统结构-活性关系（SAR）研究。这项关于丝氨酸模板类似物的SAR初步研究成功地揭示出，天然存在的穆雷霉素的复杂结构可以轻松简化，以提供抗药性强的优先抗性生物的生物活性支架。这项研究将为基于简化的丝氨酸模板的新型抗菌先导化合物的开发铺平道路。这项关于丝氨酸模板类似物的SAR初步研究成功地表明，天然存在的穆雷霉素的复杂结构可以轻松简化，以提供抗药性优先生物的生物活性支架。这项研究将为基于简化的丝氨酸模板的新型抗菌先导化合物的开发铺平道路。这项关于丝氨酸模板类似物的SAR初步研究成功地揭示出，天然存在的穆来霉素的复杂结构可以轻松简化，以提供抗药性优先生物的生物活性支架。这项研究将为基于简化的丝氨酸模板的新型抗菌先导化合物的开发铺平道路。